| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 91 | 2025 | 374 | 23.010 |
Why?
|
| Respiratory Syncytial Virus Infections | 35 | 2024 | 200 | 11.560 |
Why?
|
| Influenza Vaccines | 28 | 2025 | 144 | 9.460 |
Why?
|
| Respiratory Syncytial Virus, Human | 28 | 2024 | 155 | 8.180 |
Why?
|
| Respiratory Tract Infections | 40 | 2025 | 266 | 8.050 |
Why?
|
| South Africa | 195 | 2025 | 7596 | 6.570 |
Why?
|
| Infant | 120 | 2025 | 2244 | 6.140 |
Why?
|
| Humans | 245 | 2025 | 14537 | 5.910 |
Why?
|
| Child, Preschool | 106 | 2025 | 1748 | 5.520 |
Why?
|
| Hospitalization | 38 | 2025 | 418 | 5.480 |
Why?
|
| HIV Infections | 62 | 2024 | 5097 | 4.980 |
Why?
|
| Vaccination | 37 | 2025 | 365 | 4.930 |
Why?
|
| Child | 93 | 2025 | 2242 | 4.560 |
Why?
|
| Pneumococcal Infections | 28 | 2024 | 299 | 4.510 |
Why?
|
| Male | 136 | 2025 | 6754 | 4.190 |
Why?
|
| Female | 145 | 2025 | 9103 | 4.170 |
Why?
|
| Adolescent | 90 | 2025 | 2985 | 4.010 |
Why?
|
| Cost of Illness | 15 | 2025 | 167 | 3.890 |
Why?
|
| Coinfection | 19 | 2019 | 276 | 3.830 |
Why?
|
| Adult | 104 | 2025 | 5913 | 3.700 |
Why?
|
| Pneumococcal Vaccines | 25 | 2024 | 278 | 3.620 |
Why?
|
| Aged | 67 | 2025 | 1740 | 3.620 |
Why?
|
| Young Adult | 73 | 2025 | 2498 | 3.540 |
Why?
|
| Sentinel Surveillance | 24 | 2024 | 115 | 3.440 |
Why?
|
| Middle Aged | 83 | 2025 | 3601 | 3.400 |
Why?
|
| Seasons | 33 | 2024 | 154 | 3.010 |
Why?
|
| Streptococcus pneumoniae | 27 | 2024 | 336 | 2.970 |
Why?
|
| Prospective Studies | 39 | 2025 | 1160 | 2.920 |
Why?
|
| Infant, Newborn | 54 | 2025 | 1479 | 2.880 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 16 | 2019 | 54 | 2.770 |
Why?
|
| Incidence | 38 | 2025 | 685 | 2.460 |
Why?
|
| Communicable Diseases | 7 | 2023 | 62 | 2.130 |
Why?
|
| Vaccines, Conjugate | 13 | 2024 | 171 | 1.910 |
Why?
|
| Population Surveillance | 24 | 2020 | 325 | 1.900 |
Why?
|
| Risk Factors | 39 | 2024 | 1475 | 1.850 |
Why?
|
| Influenza B virus | 11 | 2019 | 42 | 1.770 |
Why?
|
| Prevalence | 29 | 2024 | 1192 | 1.750 |
Why?
|
| Orthomyxoviridae | 8 | 2021 | 33 | 1.720 |
Why?
|
| Virus Diseases | 6 | 2023 | 55 | 1.700 |
Why?
|
| Pandemics | 18 | 2025 | 296 | 1.670 |
Why?
|
| Diarrhea | 5 | 2018 | 76 | 1.660 |
Why?
|
| Epidemiological Monitoring | 9 | 2020 | 45 | 1.580 |
Why?
|
| Viruses | 6 | 2022 | 47 | 1.530 |
Why?
|
| Case-Control Studies | 16 | 2024 | 480 | 1.520 |
Why?
|
| Neisseria meningitidis | 6 | 2022 | 36 | 1.510 |
Why?
|
| Severity of Illness Index | 9 | 2022 | 253 | 1.510 |
Why?
|
| Global Health | 14 | 2024 | 193 | 1.460 |
Why?
|
| Cohort Studies | 16 | 2024 | 967 | 1.430 |
Why?
|
| Influenza A virus | 9 | 2019 | 28 | 1.380 |
Why?
|
| Aged, 80 and over | 23 | 2025 | 468 | 1.320 |
Why?
|
| Meningococcal Infections | 5 | 2022 | 24 | 1.230 |
Why?
|
| Hospital Mortality | 12 | 2023 | 95 | 1.220 |
Why?
|
| Disease Outbreaks | 10 | 2022 | 111 | 1.180 |
Why?
|
| Pneumonia | 3 | 2022 | 131 | 1.170 |
Why?
|
| Meningitis, Bacterial | 3 | 2024 | 38 | 1.160 |
Why?
|
| Serogroup | 14 | 2024 | 150 | 1.150 |
Why?
|
| Immunization Programs | 8 | 2021 | 81 | 1.130 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2021 | 529 | 1.130 |
Why?
|
| Pregnancy | 15 | 2023 | 1862 | 1.050 |
Why?
|
| Asymptomatic Infections | 3 | 2025 | 34 | 1.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2023 | 262 | 0.950 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 8 | 2020 | 31 | 0.940 |
Why?
|
| Cost-Benefit Analysis | 8 | 2023 | 253 | 0.910 |
Why?
|
| Antiviral Agents | 3 | 2016 | 111 | 0.910 |
Why?
|
| Family Characteristics | 6 | 2025 | 135 | 0.840 |
Why?
|
| Outpatients | 5 | 2019 | 38 | 0.810 |
Why?
|
| Epidemics | 6 | 2024 | 65 | 0.800 |
Why?
|
| Meningococcal Vaccines | 1 | 2022 | 12 | 0.750 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 256 | 0.740 |
Why?
|
| Odds Ratio | 6 | 2022 | 133 | 0.720 |
Why?
|
| Whooping Cough | 4 | 2023 | 36 | 0.710 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 104 | 0.700 |
Why?
|
| Housing | 1 | 2021 | 24 | 0.690 |
Why?
|
| Air Pollution, Indoor | 1 | 2021 | 13 | 0.680 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.680 |
Why?
|
| Vaccine Potency | 2 | 2019 | 16 | 0.680 |
Why?
|
| Rural Health | 1 | 2021 | 118 | 0.670 |
Why?
|
| Haemophilus influenzae type b | 2 | 2018 | 17 | 0.660 |
Why?
|
| History, 21st Century | 9 | 2025 | 42 | 0.640 |
Why?
|
| Premature Birth | 1 | 2021 | 80 | 0.630 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 5 | 0.630 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 3 | 2024 | 14 | 0.620 |
Why?
|
| Paramyxoviridae Infections | 4 | 2021 | 27 | 0.620 |
Why?
|
| Absenteeism | 1 | 2019 | 10 | 0.610 |
Why?
|
| Life Expectancy | 1 | 2019 | 31 | 0.610 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 43 | 0.610 |
Why?
|
| Multivariate Analysis | 9 | 2022 | 171 | 0.600 |
Why?
|
| Age Factors | 8 | 2024 | 370 | 0.590 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2015 | 10 | 0.590 |
Why?
|
| Survival Analysis | 6 | 2022 | 149 | 0.590 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 563 | 0.590 |
Why?
|
| Meningitis, Meningococcal | 3 | 2022 | 17 | 0.590 |
Why?
|
| Nasopharynx | 9 | 2023 | 151 | 0.580 |
Why?
|
| Anti-Bacterial Agents | 9 | 2025 | 293 | 0.580 |
Why?
|
| Health Resources | 1 | 2018 | 66 | 0.570 |
Why?
|
| Acute Disease | 10 | 2020 | 105 | 0.570 |
Why?
|
| Respiratory Syncytial Viruses | 4 | 2023 | 28 | 0.560 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2022 | 56 | 0.550 |
Why?
|
| Tuberculosis | 6 | 2022 | 543 | 0.550 |
Why?
|
| Health Priorities | 1 | 2018 | 62 | 0.550 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 1422 | 0.530 |
Why?
|
| Rotavirus Infections | 2 | 2014 | 46 | 0.500 |
Why?
|
| Rotavirus Vaccines | 2 | 2014 | 53 | 0.500 |
Why?
|
| Sapovirus | 1 | 2016 | 6 | 0.490 |
Why?
|
| Caliciviridae Infections | 1 | 2016 | 11 | 0.490 |
Why?
|
| Vaccines | 4 | 2022 | 86 | 0.490 |
Why?
|
| Retrospective Studies | 10 | 2022 | 799 | 0.480 |
Why?
|
| Statistics as Topic | 1 | 2015 | 31 | 0.480 |
Why?
|
| Public Health Surveillance | 6 | 2019 | 52 | 0.470 |
Why?
|
| Meningitis, Pneumococcal | 4 | 2022 | 20 | 0.460 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 11 | 0.460 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 23 | 0.450 |
Why?
|
| Measles | 3 | 2019 | 36 | 0.450 |
Why?
|
| Hospitals, Private | 1 | 2014 | 8 | 0.450 |
Why?
|
| Bronchopneumonia | 1 | 2015 | 11 | 0.450 |
Why?
|
| Bordetella pertussis | 4 | 2023 | 29 | 0.450 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2012 | 195 | 0.450 |
Why?
|
| Rural Population | 5 | 2021 | 654 | 0.450 |
Why?
|
| Metapneumovirus | 4 | 2020 | 30 | 0.430 |
Why?
|
| Time Factors | 7 | 2022 | 507 | 0.420 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2012 | 187 | 0.420 |
Why?
|
| Fever | 3 | 2019 | 26 | 0.420 |
Why?
|
| Evolution, Molecular | 3 | 2024 | 60 | 0.420 |
Why?
|
| Bacteremia | 5 | 2015 | 79 | 0.400 |
Why?
|
| Bayes Theorem | 2 | 2025 | 81 | 0.390 |
Why?
|
| Rhinovirus | 3 | 2019 | 23 | 0.380 |
Why?
|
| Polymerase Chain Reaction | 4 | 2022 | 260 | 0.370 |
Why?
|
| Antibodies, Viral | 6 | 2022 | 284 | 0.370 |
Why?
|
| Meningitis | 2 | 2022 | 26 | 0.370 |
Why?
|
| Phylogeny | 10 | 2024 | 231 | 0.370 |
Why?
|
| Corynebacterium diphtheriae | 2 | 2025 | 9 | 0.360 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 324 | 0.360 |
Why?
|
| Pneumonia, Pneumococcal | 4 | 2024 | 100 | 0.350 |
Why?
|
| United States | 7 | 2021 | 132 | 0.350 |
Why?
|
| Logistic Models | 4 | 2022 | 254 | 0.350 |
Why?
|
| Sepsis | 2 | 2022 | 102 | 0.350 |
Why?
|
| Comorbidity | 5 | 2021 | 188 | 0.340 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2025 | 198 | 0.340 |
Why?
|
| Age Distribution | 6 | 2024 | 107 | 0.340 |
Why?
|
| Haemophilus Vaccines | 2 | 2024 | 41 | 0.300 |
Why?
|
| Models, Theoretical | 3 | 2019 | 80 | 0.300 |
Why?
|
| Regression Analysis | 5 | 2017 | 133 | 0.300 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 71 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 3 | 2024 | 142 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2019 | 77 | 0.290 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 370 | 0.290 |
Why?
|
| Hepatitis B Vaccines | 2 | 2019 | 40 | 0.290 |
Why?
|
| Anti-Retroviral Agents | 4 | 2024 | 551 | 0.290 |
Why?
|
| Genotype | 8 | 2021 | 442 | 0.280 |
Why?
|
| Australia | 5 | 2020 | 48 | 0.280 |
Why?
|
| Rabies virus | 1 | 2007 | 2 | 0.280 |
Why?
|
| Rabies | 1 | 2007 | 2 | 0.280 |
Why?
|
| Seroepidemiologic Studies | 7 | 2023 | 109 | 0.280 |
Why?
|
| Models, Statistical | 3 | 2021 | 55 | 0.270 |
Why?
|
| Health Expenditures | 2 | 2025 | 39 | 0.270 |
Why?
|
| Genome, Viral | 3 | 2024 | 64 | 0.270 |
Why?
|
| Klebsiella pneumoniae | 2 | 2024 | 39 | 0.260 |
Why?
|
| Mumps | 1 | 2007 | 1 | 0.260 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2007 | 5 | 0.260 |
Why?
|
| Picornaviridae Infections | 2 | 2019 | 18 | 0.260 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2024 | 101 | 0.250 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 239 | 0.250 |
Why?
|
| Treatment Outcome | 7 | 2017 | 889 | 0.240 |
Why?
|
| Mass Screening | 2 | 2019 | 245 | 0.240 |
Why?
|
| Hospitals | 4 | 2023 | 103 | 0.240 |
Why?
|
| Community-Acquired Infections | 2 | 2024 | 102 | 0.240 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2019 | 90 | 0.240 |
Why?
|
| Malaria, Falciparum | 1 | 2005 | 39 | 0.230 |
Why?
|
| DNA, Bacterial | 3 | 2021 | 53 | 0.230 |
Why?
|
| England | 2 | 2020 | 15 | 0.230 |
Why?
|
| Health Equity | 1 | 2025 | 12 | 0.220 |
Why?
|
| Acinetobacter baumannii | 1 | 2024 | 11 | 0.220 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2025 | 135 | 0.220 |
Why?
|
| Income | 1 | 2025 | 85 | 0.220 |
Why?
|
| Pregnant Women | 2 | 2022 | 89 | 0.220 |
Why?
|
| Quality of Life | 2 | 2022 | 177 | 0.220 |
Why?
|
| Urban Population | 3 | 2021 | 257 | 0.210 |
Why?
|
| Pilot Projects | 1 | 2024 | 179 | 0.210 |
Why?
|
| Metadata | 1 | 2024 | 3 | 0.210 |
Why?
|
| Vaccines, Attenuated | 2 | 2024 | 28 | 0.210 |
Why?
|
| Bronchiolitis | 1 | 2023 | 8 | 0.210 |
Why?
|
| HIV | 2 | 2023 | 380 | 0.200 |
Why?
|
| Intention | 1 | 2023 | 23 | 0.200 |
Why?
|
| Laboratory Infection | 1 | 2023 | 5 | 0.200 |
Why?
|
| Developing Countries | 4 | 2025 | 400 | 0.200 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 42 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2025 | 225 | 0.190 |
Why?
|
| Diphtheria | 2 | 2025 | 16 | 0.190 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2012 | 472 | 0.190 |
Why?
|
| Hepatitis D | 1 | 2022 | 4 | 0.190 |
Why?
|
| Inpatients | 3 | 2019 | 30 | 0.190 |
Why?
|
| Information Storage and Retrieval | 1 | 2022 | 13 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 46 | 0.180 |
Why?
|
| Genetic Variation | 3 | 2024 | 175 | 0.180 |
Why?
|
| Perinatal Death | 1 | 2022 | 33 | 0.180 |
Why?
|
| Paramyxovirinae | 1 | 2021 | 2 | 0.180 |
Why?
|
| Candidemia | 1 | 2021 | 13 | 0.170 |
Why?
|
| Cooking | 1 | 2021 | 7 | 0.170 |
Why?
|
| Mortality | 3 | 2019 | 104 | 0.170 |
Why?
|
| Immune Evasion | 1 | 2021 | 31 | 0.170 |
Why?
|
| Linear Models | 4 | 2024 | 83 | 0.170 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 34 | 0.170 |
Why?
|
| Cryptococcosis | 2 | 2012 | 17 | 0.170 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2018 | 13 | 0.170 |
Why?
|
| Enterovirus | 2 | 2017 | 9 | 0.170 |
Why?
|
| Neutralization Tests | 1 | 2021 | 108 | 0.170 |
Why?
|
| Serotyping | 3 | 2015 | 66 | 0.170 |
Why?
|
| Enterovirus Infections | 2 | 2017 | 10 | 0.170 |
Why?
|
| Enterovirus D, Human | 2 | 2017 | 10 | 0.170 |
Why?
|
| Influenza A Virus, H5N8 Subtype | 1 | 2020 | 2 | 0.160 |
Why?
|
| Poultry Diseases | 1 | 2020 | 3 | 0.160 |
Why?
|
| Influenza in Birds | 1 | 2020 | 3 | 0.160 |
Why?
|
| Cough | 1 | 2019 | 14 | 0.160 |
Why?
|
| Child, Hospitalized | 1 | 2019 | 26 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2019 | 16 | 0.160 |
Why?
|
| Respiratory Tract Diseases | 1 | 2019 | 21 | 0.160 |
Why?
|
| Russia | 1 | 2019 | 1 | 0.160 |
Why?
|
| Carrier State | 4 | 2023 | 92 | 0.150 |
Why?
|
| Gambia | 1 | 2019 | 13 | 0.150 |
Why?
|
| Exanthema | 1 | 2019 | 2 | 0.150 |
Why?
|
| Rubella Syndrome, Congenital | 1 | 2019 | 5 | 0.150 |
Why?
|
| Computer Simulation | 2 | 2025 | 56 | 0.150 |
Why?
|
| Molecular Typing | 1 | 2019 | 12 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 74 | 0.150 |
Why?
|
| Prognosis | 1 | 2019 | 199 | 0.150 |
Why?
|
| Models, Biological | 2 | 2017 | 77 | 0.150 |
Why?
|
| Mamastrovirus | 1 | 2018 | 3 | 0.150 |
Why?
|
| Astroviridae Infections | 1 | 2018 | 3 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 22 | 0.150 |
Why?
|
| Virus Shedding | 1 | 2018 | 24 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2016 | 64 | 0.150 |
Why?
|
| Netherlands | 1 | 2018 | 2 | 0.140 |
Why?
|
| Family Health | 2 | 2015 | 16 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 385 | 0.140 |
Why?
|
| Health Facilities | 1 | 2018 | 40 | 0.140 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2018 | 4 | 0.140 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2018 | 4 | 0.140 |
Why?
|
| Vaccines, Combined | 1 | 2018 | 34 | 0.140 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 28 | 0.140 |
Why?
|
| Mothers | 1 | 2020 | 195 | 0.140 |
Why?
|
| Multilocus Sequence Typing | 2 | 2017 | 19 | 0.140 |
Why?
|
| Hepatitis B | 1 | 2019 | 125 | 0.140 |
Why?
|
| Algorithms | 2 | 2021 | 106 | 0.140 |
Why?
|
| Poisson Distribution | 2 | 2015 | 18 | 0.140 |
Why?
|
| Community Health Services | 1 | 2018 | 58 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 5 | 2018 | 181 | 0.130 |
Why?
|
| Bacterial Infections | 2 | 2015 | 54 | 0.130 |
Why?
|
| Independent Living | 1 | 2017 | 6 | 0.130 |
Why?
|
| Drug Resistance, Viral | 1 | 2018 | 278 | 0.130 |
Why?
|
| Data Collection | 1 | 2017 | 86 | 0.130 |
Why?
|
| Communicable Disease Control | 2 | 2023 | 101 | 0.130 |
Why?
|
| Kenya | 3 | 2024 | 183 | 0.130 |
Why?
|
| Chile | 3 | 2020 | 4 | 0.120 |
Why?
|
| Registries | 2 | 2017 | 91 | 0.120 |
Why?
|
| HIV Seropositivity | 2 | 2015 | 265 | 0.120 |
Why?
|
| Microscopy | 1 | 2016 | 21 | 0.120 |
Why?
|
| Cross Protection | 1 | 2016 | 4 | 0.120 |
Why?
|
| Feces | 1 | 2016 | 30 | 0.120 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 157 | 0.120 |
Why?
|
| Legionnaires' Disease | 1 | 2016 | 3 | 0.120 |
Why?
|
| Respirovirus | 1 | 2015 | 4 | 0.120 |
Why?
|
| Animals | 3 | 2020 | 1081 | 0.120 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 3 | 2024 | 42 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2015 | 39 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 132 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 150 | 0.120 |
Why?
|
| Pneumovirus Infections | 1 | 2015 | 7 | 0.120 |
Why?
|
| Genetic Drift | 1 | 2015 | 2 | 0.120 |
Why?
|
| Demography | 1 | 2015 | 105 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2015 | 22 | 0.120 |
Why?
|
| Bacterial Proteins | 2 | 2014 | 119 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 217 | 0.120 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2012 | 37 | 0.110 |
Why?
|
| Health Personnel | 1 | 2017 | 231 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 87 | 0.110 |
Why?
|
| Public Health | 3 | 2023 | 124 | 0.110 |
Why?
|
| Ceftriaxone | 1 | 2014 | 13 | 0.110 |
Why?
|
| Streptococcus agalactiae | 1 | 2016 | 202 | 0.110 |
Why?
|
| Neisseria meningitidis, Serogroup Y | 1 | 2014 | 2 | 0.110 |
Why?
|
| Acyltransferases | 1 | 2014 | 4 | 0.110 |
Why?
|
| Viral Fusion Proteins | 1 | 2013 | 13 | 0.110 |
Why?
|
| Penicillins | 3 | 2024 | 25 | 0.110 |
Why?
|
| Streptococcal Infections | 1 | 2016 | 184 | 0.100 |
Why?
|
| Selection, Genetic | 1 | 2013 | 31 | 0.100 |
Why?
|
| Child Mortality | 1 | 2014 | 96 | 0.100 |
Why?
|
| Penicillin Resistance | 2 | 2014 | 17 | 0.100 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 24 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2015 | 240 | 0.100 |
Why?
|
| Cryptococcus gattii | 1 | 2012 | 2 | 0.100 |
Why?
|
| Measles Vaccine | 1 | 2013 | 34 | 0.100 |
Why?
|
| Amphotericin B | 1 | 2012 | 10 | 0.100 |
Why?
|
| Pertussis Vaccine | 2 | 2023 | 16 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 23 | 0.100 |
Why?
|
| Molecular Epidemiology | 4 | 2014 | 47 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2012 | 40 | 0.100 |
Why?
|
| Genomics | 2 | 2023 | 109 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2012 | 54 | 0.100 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2012 | 1 | 0.090 |
Why?
|
| Dysentery, Bacillary | 1 | 2012 | 3 | 0.090 |
Why?
|
| Internet | 1 | 2012 | 12 | 0.090 |
Why?
|
| New Zealand | 2 | 2024 | 8 | 0.090 |
Why?
|
| Cross Infection | 2 | 2009 | 52 | 0.090 |
Why?
|
| Health Surveys | 1 | 2012 | 59 | 0.090 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2012 | 19 | 0.090 |
Why?
|
| Haemophilus Infections | 1 | 2011 | 23 | 0.090 |
Why?
|
| Health Services Research | 1 | 2012 | 58 | 0.090 |
Why?
|
| Genome, Bacterial | 2 | 2024 | 32 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 435 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 411 | 0.090 |
Why?
|
| World Health Organization | 3 | 2018 | 137 | 0.080 |
Why?
|
| Students | 2 | 2021 | 50 | 0.080 |
Why?
|
| Arenaviridae Infections | 1 | 2009 | 2 | 0.080 |
Why?
|
| Hemorrhagic Fevers, Viral | 1 | 2009 | 2 | 0.080 |
Why?
|
| Arenavirus | 1 | 2009 | 2 | 0.080 |
Why?
|
| Erythromycin | 2 | 2024 | 12 | 0.080 |
Why?
|
| Poverty | 2 | 2023 | 152 | 0.080 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 263 | 0.080 |
Why?
|
| Travel | 2 | 2023 | 21 | 0.080 |
Why?
|
| RNA, Viral | 3 | 2018 | 303 | 0.070 |
Why?
|
| Monte Carlo Method | 2 | 2019 | 11 | 0.070 |
Why?
|
| Ofloxacin | 1 | 2008 | 4 | 0.070 |
Why?
|
| Contact Tracing | 2 | 2024 | 48 | 0.070 |
Why?
|
| Neisseria meningitidis, Serogroup W-135 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2008 | 6 | 0.070 |
Why?
|
| Levofloxacin | 1 | 2008 | 21 | 0.070 |
Why?
|
| Endemic Diseases | 1 | 2008 | 15 | 0.070 |
Why?
|
| Jackals | 1 | 2007 | 1 | 0.070 |
Why?
|
| Dogs | 1 | 2007 | 8 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2008 | 89 | 0.070 |
Why?
|
| Cattle | 1 | 2007 | 28 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2024 | 656 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 156 | 0.060 |
Why?
|
| Anti-HIV Agents | 2 | 2012 | 1324 | 0.060 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2017 | 103 | 0.060 |
Why?
|
| Africa | 2 | 2020 | 376 | 0.060 |
Why?
|
| Health Policy | 2 | 2020 | 140 | 0.060 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2008 | 226 | 0.060 |
Why?
|
| Corynebacterium Infections | 1 | 2025 | 5 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 322 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 48 | 0.050 |
Why?
|
| Singapore | 1 | 2024 | 3 | 0.050 |
Why?
|
| Viral Interference | 1 | 2024 | 2 | 0.050 |
Why?
|
| Bacterial Load | 2 | 2014 | 32 | 0.050 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Oxygen | 1 | 2023 | 25 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2024 | 115 | 0.050 |
Why?
|
| Reproduction | 1 | 2023 | 25 | 0.050 |
Why?
|
| Private Sector | 1 | 2023 | 45 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 280 | 0.050 |
Why?
|
| Mutation | 1 | 2024 | 306 | 0.050 |
Why?
|
| Gram-Positive Bacteria | 1 | 2022 | 9 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2022 | 15 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 5 | 0.050 |
Why?
|
| Residential Facilities | 1 | 2022 | 3 | 0.050 |
Why?
|
| Laboratories | 1 | 2022 | 47 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2022 | 13 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 198 | 0.050 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 34 | 0.050 |
Why?
|
| Haemophilus influenzae | 1 | 2022 | 42 | 0.050 |
Why?
|
| Immunization | 1 | 2022 | 63 | 0.050 |
Why?
|
| Virus Cultivation | 2 | 2012 | 9 | 0.050 |
Why?
|
| Oropharynx | 2 | 2012 | 17 | 0.050 |
Why?
|
| Disease Progression | 1 | 2022 | 154 | 0.050 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 2012 | 23 | 0.050 |
Why?
|
| Markov Chains | 1 | 2021 | 22 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 106 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 44 | 0.040 |
Why?
|
| DNA Viruses | 1 | 2021 | 3 | 0.040 |
Why?
|
| Blood Donors | 1 | 2021 | 19 | 0.040 |
Why?
|
| Universities | 1 | 2021 | 34 | 0.040 |
Why?
|
| Geese | 1 | 2020 | 2 | 0.040 |
Why?
|
| Struthioniformes | 1 | 2020 | 2 | 0.040 |
Why?
|
| Ducks | 1 | 2020 | 3 | 0.040 |
Why?
|
| Animals, Wild | 1 | 2020 | 3 | 0.040 |
Why?
|
| Chickens | 1 | 2020 | 5 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 19 | 0.040 |
Why?
|
| Hepatitis B Antibodies | 1 | 2019 | 10 | 0.040 |
Why?
|
| Rubella virus | 1 | 2019 | 8 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 23 | 0.040 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2019 | 10 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2019 | 48 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 63 | 0.040 |
Why?
|
| Zanamivir | 1 | 2018 | 3 | 0.040 |
Why?
|
| Neuraminidase | 1 | 2018 | 4 | 0.040 |
Why?
|
| Oseltamivir | 1 | 2018 | 3 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2018 | 19 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 35 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2018 | 30 | 0.040 |
Why?
|
| Rifampin | 2 | 2012 | 197 | 0.040 |
Why?
|
| Schools | 1 | 2019 | 73 | 0.040 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2008 | 10 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2018 | 64 | 0.040 |
Why?
|
| Phenotype | 1 | 2018 | 158 | 0.040 |
Why?
|
| Vietnam | 1 | 2018 | 13 | 0.040 |
Why?
|
| Self Report | 1 | 2018 | 114 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 6 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2017 | 8 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 44 | 0.030 |
Why?
|
| Control Groups | 1 | 2017 | 3 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 1 | 2017 | 6 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2019 | 321 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 51 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 47 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 52 | 0.030 |
Why?
|
| Asthma | 1 | 2016 | 33 | 0.030 |
Why?
|
| Live Birth | 1 | 2016 | 5 | 0.030 |
Why?
|
| Tropical Climate | 1 | 2016 | 4 | 0.030 |
Why?
|
| Legionella | 1 | 2016 | 3 | 0.030 |
Why?
|
| Legionellosis | 1 | 2016 | 3 | 0.030 |
Why?
|
| Legionella pneumophila | 1 | 2016 | 3 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 124 | 0.030 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2016 | 14 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 227 | 0.030 |
Why?
|
| Streptococcal Vaccines | 1 | 2016 | 47 | 0.030 |
Why?
|
| Hemoglobinopathies | 1 | 2015 | 3 | 0.030 |
Why?
|
| Dengue | 1 | 2015 | 5 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2015 | 13 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 54 | 0.030 |
Why?
|
| Suburban Population | 1 | 2014 | 9 | 0.030 |
Why?
|
| Malnutrition | 1 | 2015 | 56 | 0.030 |
Why?
|
| Viral Load | 1 | 2018 | 819 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 2 | 0.030 |
Why?
|
| Egypt | 1 | 2013 | 4 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 111 | 0.030 |
Why?
|
| Guatemala | 1 | 2013 | 8 | 0.030 |
Why?
|
| Weather | 1 | 2013 | 7 | 0.030 |
Why?
|
| Bangladesh | 1 | 2013 | 17 | 0.030 |
Why?
|
| Thailand | 1 | 2013 | 26 | 0.030 |
Why?
|
| Climate | 1 | 2013 | 5 | 0.030 |
Why?
|
| China | 1 | 2013 | 21 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2015 | 353 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2014 | 51 | 0.030 |
Why?
|
| Pharynx | 1 | 2012 | 4 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2012 | 7 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2012 | 21 | 0.020 |
Why?
|
| Malaria | 1 | 2015 | 213 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 32 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 43 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 89 | 0.020 |
Why?
|
| Shigella | 1 | 2012 | 2 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 99 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 106 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 32 | 0.020 |
Why?
|
| Australasia | 1 | 2011 | 2 | 0.020 |
Why?
|
| South America | 1 | 2011 | 27 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2011 | 23 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 44 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 272 | 0.020 |
Why?
|
| Ribavirin | 1 | 2009 | 15 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 21 | 0.020 |
Why?
|
| Zambia | 1 | 2009 | 115 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2008 | 9 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2008 | 59 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2008 | 13 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 65 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 139 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 38 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 143 | 0.020 |
Why?
|